Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | YARS1 | P54577 | 2/20 | 0.45 |
| ▸ | TPH1 | P17752 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL608841 | 1.00 | SLC7A5 (0.58) | SLC7A5NPC1RAB9AYARS1TPH1 | |
| Phenylalanine SCHEMBL8081643 | 0.90 | SLC7A5 (0.56) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL3649167 | 0.86 | TPH1 (0.42) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL10889174 | 0.81 | MME (0.44) | NPC1RAB9ARECQL | |
| SCHEMBL10889181 | 0.81 | MME (0.44) | NPC1RAB9ARECQL | |
| Tyrosine SCHEMBL6454113 | 0.80 | SLC7A5 (0.71) | SLC7A5YARS1TPH1PTGS1ALPI | |
| Tyrosine SCHEMBL6454106 | 0.80 | SLC7A5 (0.71) | SLC7A5YARS1TPH1PTGS1ALPI | |
| Tyrosine SCHEMBL27841332 | 0.80 | SLC7A5 (0.71) | SLC7A5YARS1TPH1PTGS1ALPI | |
| Tyrosine SCHEMBL28768017 | 0.78 | SLC7A5 (0.67) | SLC7A5YARS1TPH1PTGS1ALPI | |
| SCHEMBL838650 | 0.78 | NPC1 (0.54) | SLC7A5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008185-A1 | Treatment and Prophylaxis of Amyloidosis | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3693470-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | Prothena Therapeutics Limited (IE) | 2020-08-12 | — | — | EP | disclosed |
| US-20180360934-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | PROTHENA THERAPEUTICS LIMITED (IE) | 2018-12-20 | — | — | US | disclosed |
| US-20170081396-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | PROTHENA THERAPEUTICS LIMITED (IE) | 2017-03-23 | — | — | US | disclosed |
| EP-2237803-B1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | PROTHENA BIOSCIENCES LTD (IE) | 2015-07-01 | — | — | EP | disclosed |
| US-20150158937-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | ONCLAVE THERAPEUTICS LIMITED (IE) | 2015-06-11 | — | — | US | disclosed |
| EP-1594969-B1 | ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA | JANSSEN SCIENCES IRELAND UC (IE) | 2015-05-20 | — | — | EP | disclosed |
| US-8791243-B2 | Treatment and prophylaxis of amyloidosis | ONCLAVE THERAPEUTICS LIMITED (IE) | 2014-07-29 | — | — | US | disclosed |
| US-20140134103-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2730659-A2 | Treatment and Prophylaxis of Amyloidosis | Elan Pharmaceuticals Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20080279873-A1 | ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA | WYETH LLC | 2008-11-13 | — | — | US | disclosed |
| WO-2008042024-A2 | NEUROACTIVE FRAGMENTS OF APP | ELAN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080044406-A1 | Neuroactive fragments of APP | ELAN PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| CN-101052417-A | Prevention and treatment of synucleinopathic and amyloidogenic disease | ELAN PHARM INC (US) | 2007-10-10 | — | — | CN | disclosed |
| US-20060188512-A1 | Active immunization to generate antibodies to solble a-beta | WYETH LLC | 2006-08-24 | — | — | US | disclosed |
| EP-1594969-A4 | ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA | NEURALAB LTD (BM) | 2006-07-26 | — | — | EP | disclosed |
| CN-1745175-A | Active immunization to generate antibodies to soluble A-beta | NEURALAB LTD (BM) | 2006-03-08 | — | — | CN | disclosed |
| EP-1594969-A2 | ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA | Neuralab Limited (BM) | 2005-11-16 | — | — | EP | disclosed |
| US-20040213800-A1 | Active immunization to generate antibodies to soluble A-beta | WYETH LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004069182-A2 | ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA | NEURALAB LIMITED (BM) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134103-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | TTR, APP, MME | SLC7A5 1629/4885NPC1 1355/4885RAB9A 3800/4885 |
| US-20180360934-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | TTR, APP, MME | SLC7A5 1629/4885NPC1 1355/4885RAB9A 3800/4885 |
| US-20040213800-A1 | Active immunization to generate antibodies to soluble A-beta | APP, APBA1, BACE1 | SLC7A5 1506/4885NPC1 2860/4885RAB9A 2945/4885 |
| US-20150158937-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | TTR, APP, MME | SLC7A5 1629/4885NPC1 1355/4885RAB9A 3800/4885 |
| US-20080279873-A1 | ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA | APP, APBA1, BACE1 | SLC7A5 1762/4885NPC1 2600/4885RAB9A 2838/4885 |
| US-20170081396-A1 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS | TTR, APP, MME | SLC7A5 1629/4885NPC1 1355/4885RAB9A 3800/4885 |
| US-20060188512-A1 | Active immunization to generate antibodies to solble a-beta | APP, APBA1, BACE1 | SLC7A5 1434/4885NPC1 3116/4885RAB9A 1811/4885 |
| US-20210008185-A1 | Treatment and Prophylaxis of Amyloidosis | TTR, APP, MME | SLC7A5 1629/4885NPC1 1355/4885RAB9A 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.